Department of Pathology and Neurology, University of Maryland School of Medicine, Baltimore, Maryland (C-YH).
Center for Genetic Medicine Research (C-YH, MB, HG-D).
J Neuropathol Exp Neurol. 2020 Jan 1;79(1):67-73. doi: 10.1093/jnen/nlz115.
Neuronal/mixed glioneuronal tumors are central nervous system neoplasms composed of neoplastic neuronal cell components or a mixture of glial and neuronal elements. They occur in cerebral hemispheres, posterior fossa, and spinal cord. Compared with other tumors at these locations, diencephalic neuronal/glioneuronal tumors are very rare and therefore not well characterized. We hereby performed clinicopathologic evaluation on 10 neuronal/glioneuronal tumors arising from the diencephalic region. Morphologically, these tumors resemble their histologic counterparts in other locations, except that lymphocytic infiltrates and microcalcifications are more common than Rosenthal fibers or eosinophilic granular bodies. The BRAFV600 mutation rate is 75%. Given the high percentage of samples being small biopsy specimens, the subtle histologic features and molecular findings greatly aided in establishing the pathologic diagnosis in several cases. At a median follow-up of 42 months, 71% of the tumors demonstrated radiological recurrence or progression, with median progression-free survival of 18 months. Recurrence/progression is observed in tumors across different histologic subtypes, necessitating additional therapies in 56% of the cases. Despite their bland histology, diencephalic neuronal/glioneuronal tumors are not clinically indolent. Their frequent recurrences warrant a close follow-up, and the prevalent BRAF mutation makes MAPK pathway inhibition a plausible treatment option when conventional therapies fail.
神经元/混合性神经胶质细胞瘤是一种中枢神经系统肿瘤,由肿瘤性神经元细胞成分或神经胶质和神经元成分的混合物组成。它们发生在大脑半球、后颅窝和脊髓。与这些部位的其他肿瘤相比,间脑神经元/神经胶质细胞瘤非常罕见,因此特征描述不足。我们在此对 10 例发生于间脑区域的神经元/神经胶质细胞瘤进行了临床病理评估。形态学上,这些肿瘤与其他部位的组织学对应物相似,只是淋巴细胞浸润和微钙化比 Rosenthal 纤维或嗜酸性颗粒体更常见。BRAFV600 突变率为 75%。鉴于大部分样本为小活检标本,细微的组织学特征和分子发现极大地帮助了几个病例的病理诊断。在中位随访 42 个月时,71%的肿瘤出现影像学复发或进展,无进展生存期的中位数为 18 个月。不同组织学亚型的肿瘤均有复发/进展,56%的病例需要额外的治疗。尽管这些肿瘤的组织学表现温和,但间脑神经元/神经胶质细胞瘤在临床上并非惰性。它们频繁的复发需要密切随访,而且普遍存在的 BRAF 突变使得 MAPK 通路抑制成为常规治疗失败时的一种合理治疗选择。